PERTH, AUSTRALIA: April 10, 2013 – Phylogica Ltd (ASX:PYC, XETRA:PH7), a leading Australian peptide drug discovery company, has engaged Griffin Securities, a specialty investment bank located in New York City, to conduct a formal process for evaluating strategic opportunities available to the Company.
Phylogica’s CEO, Dr Paul Watt, commented: “Over the past few years we have continued to demonstrate the value of our Phylomer platform through the progress of our four alliances with top-10 pharmaceutical companies. We have also further validated the Phylomer approach through our in-house R&D. This has established our technology at the forefront of peptide drug discovery, particularly in the burgeoning new field of intracellular delivery of biological drugs. In addition, Phylomers have potential applications in animal health, agricultural biotech and industrial products.”
“As a result, Phylogica has caught the attention of companies wanting to access our next generation peptide drug discovery capabilities, but also companies that are interested in additional uses of the platform,” added Dr Watt.
For further information please download PDF below:
